期刊文献+

中国胃癌患者HER2蛋白表达与临床病理学参数及预后的关系 被引量:42

Association of HER2 protein expression with clinicopathologic features and prognosis in Chinese patients with gastric carcinoma
原文传递
导出
摘要 目的 评估中国胃癌人群中HEB2蛋白表达的流行病学情况,分析其与患者临床病理学参数之间的关系,探讨HEB2蛋白表达与胃癌患者预后的关系.方法 使用免疫组织化学方法检测胃癌患者中HER2蛋白的表达,以修订后HereepTest评分标准进行评分.x2检验分析HEB2蛋白表达与胃癌患者临床病理学参数之间的关系.生存分析应用Kaplan-Meier法,生存率比较采用Logrank 检验.结果 860例患者中位年龄59岁,男女比例为2.06∶1,其中进展期胃癌患者为774例.使用修订后的HercpTest评分标准评判HER2蛋白阳性表达(3+)的患者为77例(9.0%,77/860),其中进展期胃癌中的HER2阳性表达患者是69例,占进展期胃癌的8.9%(69/774).HEB2蛋白在胃癌中的阳性表达与肿瘤分化、Lauren分型及WHO分型相关,与年龄、性别、肿瘤发生部位及临床分期不相关.生存分析提示HER2蛋白阳性表达的胃癌患者生存率与阴性表达者无明显差异.结论 虽然胃癌HER2蛋白的阳性表达与肿瘤分化及组织学类型相关,但其可能不是胃癌患者的独立预后因子;HER2蛋白在胃癌中的阳性表达可能不影响胃癌患者的预后. Objective To evaluate the epidemiological status of HER2 protein expression in Chinese patients with gastric carcinoma,and to study its clinical and prognostic significance and the association with the clinicopathological features.Methods The clinical data were reviewed in 860 patients with gastric carcinoma admitted to Guangdong General Hospital from 2003 to 2010.The HER2 status Was evaluated using immunohistochemistry(IHC).The modified Heroep Test scoring criterion Was used to assess HER2 protein expression.The association between HER2 expression and clinicopathological features was analyzed by X2 test.Kaplan-Meier analysis,log-rank test and Cox regression model were used for the survival analysis.Results The median age of the patients Was 59 years, and the male-to-female ratio was 2.06∶1.Positive expression of HER2 protein(3+)was found in 77(9.0%)cases of gastric carcinoma,and in 69(8.9%)edvanced gastric cancers.There waS significantly positive association between HER2 overexpression and tumor differentiation, Lanren claasification and WHO classification.No significant association Was observed between HER2 protein expression and patients'age,gender,tumor location and clinical stage.There waS no statistically significant difference in survival rate between patients with positive HER2expression and negative ones. Conclusion Though there WaS significantly positive association between HER2 expression status and tumor differentiation,histological type,it may be of limited prognostic value in gastric cancer patients.
出处 《中华病理学杂志》 CAS CSCD 北大核心 2011年第5期296-299,共4页 Chinese Journal of Pathology
关键词 胃肿瘤 基因 ERBB-2 免疫组织化学 预后 Stomach neoplasms Genes,erbB-2 Immunohistochemistry Prognosis
  • 相关文献

参考文献16

  • 1Kamangar F,Dores GM,Anderson WF.Patterns of cancer incidence,mortality,and prevalence across five continents:defining priorities to reduce cancer disparities in different geographic regions of the world.J Clin Oncol,2006,24(14):2137-2150.
  • 2Akiyama T,sudo C,Oguwara H,et al.The product of the human c-erbB-2 gene:a 185-kilodalton glycoprotein with tyrosine kinase activity.Science,1986,232(4758):1644-1646.
  • 3Koeppen HK,wright BD,Burt AD,et al.Overexpression of HER2/neu in solid tumours:an immunohistochemical survey.Histopathology,2001,38(2):96-104.
  • 4Takehana T,Kunitomo K,Kono K,et al.Status of c-erbB-2 in gastric adenocareinoma:a comparative study of immunohistochemistry,fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay.Int J Cancer,2002,98(6):833-837.
  • 5Sakai K,Moil S,Kawamoto T,et al.Expression of epidermal growth factor receptors on normal human gastric epitheha and gastric carcinomas.J Natl Cancer Inst,1986,77(5):1047-1052.
  • 6Fnjimoto-Ouchi K,Sckiguchi F,Yasnno H,et al.Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.Cancer Chemother Phannacol,2007,59(6):795-805.
  • 7Yonemura Y,Ninomiya I,Yamaguchi A,et al.Evaluation of immunoreactidty for erbB-2 protein as a marker of poor short term prognosis in gastric cancer Cancer Res,1991,51(3):1034-1038.
  • 8Uchino S,Tsuda H,Maruyama K,et al.Overexprossion of c-erbB-2 protein in gastric cancer.Its correlation with long-term survival of patients.Cancer,1993.72(11):3179-3184.
  • 9Hofmann M,Stoss O,Shi D,et al.Assessment of a HEB2 scoring system for gastric cancer:results from a validation study.Histopathology,2008,52(7):797-805.
  • 10Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy velug chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3,open-label,randomised controlled trial.Lancet,2010,376(9742):687-697.

二级参考文献16

  • 1Ross JS, Fletcher JA. HER-2/neu (cerb-B2) gene and protein in breast cancer [J]. Am J Chin Pathol, 1999,112 (Suppl 1 ) : S53-S67.
  • 2Menard S, Casalini P, Campiglio M, et al. HER2 overexpression in various tumor types, focusing on its relationship to the development of invasive breast cancer [J]. Ann Oncol, 2001,12(Suppl 1) :S15-S19.
  • 3Varis A, Zaika A, Puolakkainen P, el hi. Coamplified and overexpressed genes at erbB2 locus in gastric cancer [J]. Int J Cancer, 2004, 109(4) : 548-553.
  • 4Park DI, Yun JW, Park JH, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer [J]. Dig Dis Sci, 2006,51(8) : 1371-1379.
  • 5Kim MA, Jung EJ, Lee HS, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction [ J ]. Hum Pathol, 2007,38 (9) : 1386-1393.
  • 6Uchino S, Tsuda H, Maruyama K, et al. Overexpression of c- erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients [ J ]. Cancer, 1993,72 ( 11 ) : 3179-3184.
  • 7Mizutani T, Onda M, Tokunaga A, et al. Relationship of C- erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer [J]. Cancer, 1993,72 ( 2 ) : 2033-2038.
  • 8Yano T, Ochiai A, Doi T, et al. Expression of HER2 in gastric cancer: comparison between protein expression and gene amplification using a new commercial kit [J]. J Clin Oncol, 2004,22: 14S (Abstr 4053).
  • 9Tubbs RR, Pettay JD, Roche PC, et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message [ J ]. J Clin Oncol, 2001,19 ( 10 ) : 2714-2721.
  • 10Bae CD, Juhnn YS, Park JB. Post-transcriptional control of cerb B-2 overexpression in stomach cancer cells[J].Exp Mol Med, 2001,33(1):15-19.

共引文献24

同被引文献335

引证文献42

二级引证文献151

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部